期刊论文详细信息
Journal of Veterinary Internal Medicine
Bioequivalence of Orally Administered Generic, Compounded, and Innovator‐Formulated Itraconazole in Healthy Dogs
D.I. Mawby1  J.C. Whittemore1  S. Genger1 
[1] Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN
关键词: Bioavailability;    Blastomyces;    Fungal infection;    Histoplasma;    Pneumonia;   
DOI  :  10.1111/jvim.12219
来源: Wiley
PDF
【 摘 要 】

Abstract

Background

Itraconazole is commonly used to treat systemic fungal infections in dogs, but problems exist with absorption and cost.

Objective

To determine oral bioequivalence of generic and compounded itraconazole compared to original innovator (brand name) itraconazole in healthy dogs.

Animals

Nine healthy, adult research Beagle dogs.

Methods

A randomized, 3-way, 3-period, crossover design with an 8-day washout period. After a 12-hour fast, each dog received 100 mg (average: 10.5 mg/kg) of either innovator itraconazole, an approved human generic capsule, or compounded itraconazole (compounded using a commercially available compounding vehicle) with a small meal. Plasma was collected at predetermined intervals for high pressure liquid chromatography analysis. Concentration data were analyzed using noncompartmental pharmacokinetics to determine area under the curve (AUC), peak concentration (CMAX), and terminal half-life. Bioequivalence tests compared generic and compounded itraconazole to the reference formulation.

Results

Average ratios of compounded and generic formulations to the reference formulation of itraconazole for AUC were 5.52% and 104.2%, respectively, and for CMAX were 4.14% and 86.34%, respectively. A test of bioequivalence using 2 one-sided tests and 90% confidence intervals did not meet bioequivalence criteria for either formulation.

Conclusion and Clinical Importance

Neither generic nor compounded itraconazole is bioequivalent to the reference formulation in dogs. However, pharmacokinetic data for generic formulation were similar enough that therapeutic concentrations could be achieved. Compounded itraconazole produced such low plasma concentrations, it is unlikely to be effective; therefore, compounded itraconazole should not be used in dogs.

【 授权许可】

Unknown   
Copyright © 2013 by the American College of Veterinary Internal Medicine

【 预 览 】
附件列表
Files Size Format View
RO202107150007194ZK.pdf 116KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:1次